Business
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that a poster presentation was given over the weekend at ACR Convergence, the annual meeting of the American College of Rheumatology. The presentation highlighted that levels of urinary soluble ALCAM (sALCAM) could be a potential biomarker of disease severity in lupus nephritis (LN) and indicative of a patient’s response to treatment. The meeting, the world’s premier rheumatology conference, is taking place November 10 – 14, 2022 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.\n\n“The findings from this research represent an important step in the clinical development of itolizumab, which targets the CD6-ALCAM pathway and provides further support for its potential to be a meaningful therapy for lupus nephritis patients,” said Dr. Maple Fung, nephrologist and senior vice president of clinical development at Equillium. “Lupus nephritis is a serious illness that can lead to devastating long term complications including end stage kidney disease. A potential biomarker that can be diagnostic in a less invasive manner than a kidney biopsy, such as a urine sample, would be a tremendous advancement in the field. If that same biomarker could be indicative of response to treatment, it could be a breakthrough in the diagnosis and follow-up care for patients with this complex disease.”\n\nTitle: Urine ALCAM is a Strong Predictor of Lupus Nephritis\nFirst Author: Dalena Chu, Associate Scientist, Equillium, Inc.\nSession Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations\nPoster Number: 1478\n\nKey Highlights, Summary and Conclusions from Presentation:\n\n\nResearch demonstrated that urine ALCAM is a biomarker of disease severity in LN that could be indicative of disease progression and/or response to treatment\n\n\nUrine ALCAM correlates with currently accepted measures of LN, including UPCR (urine protein-to-creatinine ratio) and renal SLEDAI (systemic lupus erythematosus disease activity index)\n\n\nData suggests that urine ALCAM reflects changes in LN and could potentially be used in combination with other measures to inform clinicians of a patient’...